Post-acute Sequelae of COVID-19

Top drugs studied for this disease

All Approvals Safety alerts Label changes Trial results Research Guidance Withdrawals

CLINICAL_TRIALS research · 2024-07-16
Clinical Trial Update: Glutamatergic Modulation as a Treatment for Depressive Symptoms Among Patients With Post-acute Sequelae of COVID (PASC): A Pilot Trial [Phase 2]
Phase 2 pilot trial assessing glutamatergic modulation to treat depressive symptoms in patients with Post-acute Sequelae of COVID-19; the st…